Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment

Table 1 Relationship between CD155 expression and pathological characteristics

	CD155 expression		P value
	Negative (n = 78)	Positive (n = 48)
Age1, mean ± SD (yr)	58.2 ± 13.87	57.8 ± 13.26	0.914
Histological grade2, n (%)			0.112
I	11 (15.3)	2 (4.3)
II	47 (65.3)	32 (69.6)
III	14 (19.4)	12 (26.1)
TNM stage2, n (%)			0.662
I	20 (27.0)	10 (21.3)
II	39 (52.7)	28 (59.6)
III	12 (16.2)	6 (12.8)
IV	3 (4.1)	3 (6.4)
Molecular subtype3, n (%)			0.002
Luminal A	49 (77.8)	14 (22.2)
Luminal B	16 (51.6)	15 (48.4)
HER2 over-expression	5 (50.0)	5 (50.0)
Triple negative	3 (27.3)	8 (72.7)

¹Wilcoxon rank sum test.

²Spearman correlation test.

³Chi-square test. TNM: Tumor node metastasis.

Table 2 Association between CD155 expression and percentage of tumor infiltrating lymphocytes phenotypes¹

	CD155 expression		P value
TILs phenotypes	Negative (n = 78)	Positive (n = 48)
CD4+ TILs, mean ± SD	60% ± 22%	61% ± 22%	0.788
CD4+/PD-1+ TILs, mean ± SD	21% ± 20%	30% ± 19%	0.004
CD4+/PD-1- TILs, mean ± SD	39% ± 20%	31% ± 19%	0.032
CD8+ TILs, mean ± SD	23% ± 13%	24% ± 11%	0.342
CD8+/PD-1+ TILs, mean ± SD	4% ± 5%	5% ± 5%	0.280
CD8+/PD-1- TILs, mean ± SD	19% ± 10%	20% ± 9%	0.437

¹Wilcoxon rank sum test. TILs: Tumor infiltrating lymphocytes.

Table 3 Association between CD155 expression and cell counts of tumor infiltrating lymphocytes phenotypes¹

TILs phenotypes	CD155 expression		P value
	Negative (n = 78)	Positive (n = 48)
CD4+ TILs, mean ± SD	54 ± 46	87 ± 93	0.041
CD4+/PD-1+ TILs, mean ± SD	20 ± 24	47 ± 57	0.002
CD4+/PD-1- TILs, mean ± SD	34 ± 30	41 ± 45	0.658
CD8+ TILs, mean ± SD	21 ± 20	37 ± 44	0.040
CD8+/PD-1+ TILs, mean ± SD	4 ± 5	7 ± 13	0.069
CD8+/PD-1- TILs, mean ± SD	17 ± 17	30 ± 35	0.040

¹Wilcoxon rank sum test. TILs: Tumor infiltrating lymphocytes.